Engineered immune cells target and destroy glioblastoma in animal models
With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy—which involves strengthening the immune system ...
Nov 20, 2025
0
19









